OMass Therapeutics

OMass Therapeutics, formerly known as OMass Technologies and a spin out of of University of Oxford, is a biotechnology company focused on developing small molecule compounds, using its OdyssION technology platform, for the potential treatment of rare diseases and immunological diseases.In April 2022, the company announced an USD 100 million Series B financing round led by GV, Northpond Ventures, Sanofi Ventures, Syncona, Oxford Science Enterprises and Oxford University.In February 2020, the company completed an extended series A financing of GBP 27.5 million (US$35.872) from existing investors Syncona Ltd and Oxford Sciences Innovation (OSI) who joined in the round with GBP 0.5 (US$0.652) million from the University of Oxford and contributed GBP16.6 (US$21.654) million and GBP10.4 (US$13.566) million respectively, that came after an initial Series A investment of GBP 14 (US$18.262) million in 2018 bringing the total series A to GBP 41.5 (US$54.135) million.In November 2018, the company